RESUMEN
BACKGROUND: Gigantic left atrium is defined in the current literature as an excessive dilatation of the left atrium above 65mm. Chronic mitral valve disease is associated with the development of thrombus in the left atrium in up to 19% of all cases of mitral insufficiency and appropriate treatment must be initiated to prevent thromboembolic events. In order to diagnose thrombi in the left atrium or left atrial appendage, various imaging methods may be used, including cardiac magnetic resonance. CASE PRESENTATION: The case report describes a 73-year-old male who developed recurrent sessile thrombus on the posterior wall of the gigantic left atrium. A large thrombus was first detected following mitral valve surgery despite effective vitamin K antagonist anticoagulation therapy. Echocardiography and cardiac magnetic resonance were used within the diagnostic procedure and to monitor the treatment outcomes. Cardiac magnetic resonance was shown to be beneficial as it provided a more precise description of the intra-atrial masses located on the posterior left atrial wall, and in such situations, is of greater benefit than standard echocardiography. This led to the surgical removal of the intra-atrial mass; nevertheless, it was quickly followed by the recurrence of the thrombus. The anticoagulant therapy was adjusted and fortified by the introduction of acetylsalicylic acid and sequentially clopidogrel, but this also did not resolve the thrombus formation. Finally, employing a combination of rivaroxaban and clopidogrel resulted in partial thrombus regression. Therefore, various pathophysiological aspects of thrombus formation and used anticoagulation strategies are discussed. CONCLUSIONS: We describe a unique case of a recurrent thrombus located on the posterior wall of the gigantic left atrium. Cardiac magnetic resonance was shown to be beneficial in providing a more precise description of the intra-atrial masses located on the posterior left atrial wall as compared to standard echocardiographic examination. Development of a thrombus after mitral valve surgery despite effective anticoagulant therapy and its final resolution by introducing a combination of rivaroxaban and clopidogrel highlights the complex etiopathogenesis of thrombus formation. This supports the potential use of this combination in tailoring an individual personalized therapy for patients with recurrent atrial thrombi.
Asunto(s)
Clopidogrel/administración & dosificación , Inhibidores del Factor Xa/administración & dosificación , Atrios Cardíacos/efectos de los fármacos , Cardiopatías/tratamiento farmacológico , Inhibidores de Agregación Plaquetaria/administración & dosificación , Rivaroxabán/administración & dosificación , Trombosis/tratamiento farmacológico , Anciano , Quimioterapia Combinada , Atrios Cardíacos/diagnóstico por imagen , Atrios Cardíacos/cirugía , Cardiopatías/diagnóstico por imagen , Cardiopatías/etiología , Cardiopatías/cirugía , Implantación de Prótesis de Válvulas Cardíacas/efectos adversos , Humanos , Masculino , Anuloplastia de la Válvula Mitral/efectos adversos , Insuficiencia de la Válvula Mitral/diagnóstico por imagen , Insuficiencia de la Válvula Mitral/cirugía , Recurrencia , Trombectomía , Trombosis/diagnóstico por imagen , Trombosis/etiología , Trombosis/cirugía , Resultado del TratamientoRESUMEN
Bioresorbable Vascular Scaffolds (BVS) are polymer-based materials implanted in the coronary arteries in order to treat atherosclerotic lesions, based on the concept that once the lesion has been treated, the material of the implanted stent will undergo a process of gradual resorption that will leave, in several years, the vessel wall smooth, free of any foreign material and with its vasomotion restored. However, after the first enthusiastic reports on the efficacy of BVSs, the recently published trials demonstrated disappointing results regarding long-term patency following BVS implantation, which were mainly attributed to technical deficiencies during the stenting procedure. Intracoronary imaging could play a crucial role for helping the operator to correctly implant a BVS into the coronary artery, as well as providing relevant information in the follow-up period. This review aims to summarize the role of intracoronary imaging in the follow-up of coronary stents, with a particular emphasis on the role of intravascular ultrasound and optical coherence tomography for procedural guidance during stent implantation and also for follow-up of bioabsorbable scaffolds.
Asunto(s)
Implantes Absorbibles , Stents Liberadores de Fármacos , Estudios de Seguimiento , Humanos , Diseño de Prótesis , StentsRESUMEN
The objective of this study was to assess the efficacy and safety of liposomal heparin spray-a new formula of topical heparin delivery. This was a randomized, multicenter, controlled open clinical trial with 2 parallel groups. Forty-six outpatients with clinical signs of superficial venous thrombosis (SVT) were treated with either topical liposomal heparin spraygel (LHSG) (Lipohep Forte Spraygel, 4 puffs of 458 IU tid (n = 22) or with low-molecular-weight heparin (LMWH) (Clexane 40 mg once a day (n = 24), administered subcutaneously (sc). Main outcome measures were efficacy parameters (improvement of local symptoms-pain control and planimetric evaluation of erythema size, duplex Doppler assessment of thrombus regression) and safety parameters (documentation of adverse events, with particular reference to deep vein thrombosis [DVT] by duplex sonography, and patients' and investigators' assessment of drug tolerance). Patients' and investigators' subjective assessment of efficacy of treatment and change in basic biochemical parameters were defined as secondary outcome measures. Statistical analysis was performed with use of Wilcoxon test, Mann-Whitney U-test and Chi-square test. Regression of SVT-related symptoms, including pain, erythema, and thrombus presence, was shown as comparable in LHSG and LMWH groups. These results were corroborated by efficacy assessment by investigators and patients. Three cases of deep venous thrombosis in heparin spraygel and 1 in heparin sc group were reported. No significant adverse reactions were observed in the spraygel group, but 1 serious allergic reaction was observed in the LMWH group. Tolerance of new formula heparin was assessed as good. Heparin spraygel-a new topical mode of heparin application, seems a promising method of heparin delivery. This initial study has demonstrated comparable efficacy and safety of LHSG and LMWH in local treatment of SVT. These findings should be confirmed by further extensive study that will reach appropriate statistical power to support such conclusion, for despite heparin treatment, significant risk of DVT was demonstrated in both groups.
Asunto(s)
Enoxaparina/administración & dosificación , Fibrinolíticos/administración & dosificación , Heparina/administración & dosificación , Tromboflebitis/tratamiento farmacológico , Trombosis de la Vena/tratamiento farmacológico , Administración Tópica , Adulto , Aerosoles , Anciano , Enoxaparina/efectos adversos , Femenino , Heparina/efectos adversos , Humanos , Inyecciones Subcutáneas , Liposomas , Masculino , Persona de Mediana Edad , Dimensión del Dolor , Tromboflebitis/diagnóstico por imagen , Resultado del Tratamiento , Ultrasonografía Doppler Dúplex , Trombosis de la Vena/diagnóstico por imagenRESUMEN
Ventricular septal rupture is a potentially fatal complication of acute myocardial infarction. The key to management of this critical condition is an aggressive approach to haemodynamic stabilization and surgical closure of the rupture. Where there is a small rupture and the patient is in a haemodynamically stable condition, surgery can be delayed with the prospect of achieving better perioperative results. However, in unstable critically ill patients either immediate surgery or extracorporeal membranous oxygenation support and delayed surgery is indicated. In some patients, trans-catheter closure may be considered as an alternative to surgery.
RESUMEN
UNLABELLED: The aim of this paper is to elucidate the relation between laboratory markers and coronary artery disease (CAD). METHODS: The study involved 1254 consecutive patients with suspected or known CAD referred for coronary angiography. The blood samples including blood cell count, C-reactive protein, fibrinogen, uric acid, creatinine, and lipid spectrum were obtained after overnight fasting. One hundred and thirty-three patients were excluded due to incomplete records or inacceptable laboratory values. Differences among groups were tested with one-way ANOVA and Bonferroni post-hoc test for continuous variables and with chi-square test for categorical variables. Univariate and multivariate logistic regression was adopted for the analysis of risk factors and development of models for classification of patients into clinical categories. RESULTS: The linear logistic regression showed association of patient's biochemical markers with the presence of disease. Both acute and chronic CAD were associated with leukocyte count (Odds ratios 1.45 and 1.26), CRP (1.13; 1.05), fibrinogen (4.23; 1.95), uric acid (1.27; 1.38), creatinine (1.04; 1.04), HDL cholesterol (0.07; 0.12), triglycerides (1.4; 1.52) and glucose (1.56; 1.39). Presence of insignificant atherosclerosis was influenced only by fibrinogen (OR 1.73), creatinine (1.02), HDL cholesterol (0.5) and glucose level (1.23). There was no difference between one- and multivessel disease in laboratory values. CONCLUSION: Leukocyte count, CRP level, triglycerides and uric acid are associated with the presence of both acute and chronic ischaemic heart disease, but not with number of stenosed vessels. In addition, glycemia, HDL cholesterol and namely fibrinogen and creatinine have relation to occurence of insignificant atherosclerosis.